The Pillars for Sustained Growth of Magnetic Resonance Imaging Pathway for Prostate Cancer Diagnosis: Quality, Reproducibility, Accessibility, Cost Effectiveness, and Training
Publication date: Available online 23 January 2020Source: European UrologyAuthor(s): Andre Luis Abreu
Publication date: Available online 20 February 2020Source: European UrologyAuthor(s): Juan Morote, Anna Celma, Jacques Planas
Publication date: March 2020Source: Journal of Vascular and Interventional Radiology, Volume 31, Issue 3, SupplementAuthor(s): B. Choi, H. Jung, B. Yu, H. Choi, J. Lee, D. Kim
This study aimed to evaluate whether IRE combining indoleamine 2,3-dioxygenase inhibitor (IDOi, Epacadostat) loaded iron oxide nanocarriers (IDOi-INCs) can serve as a magnetic resonance imaging (MRI) –guided local ablation strategy for enhancing prostate cancer immunotherapy.
We report 12-month outcomes from the TULSA-PRO Ablation Clinical Trial (TACT) pivotal study.
To evaluate the changes of 3 Tesla (3T) mpMRI and prostate-specific antigen (PSA) parameters before and during multiple time points after whole gland prostate cancer (PCa) treatment using MRI-guided directional transurethral ultrasound ablation (TULSA)
Focal laser ablation (FLA) for prostate cancer is usually performed in an MRI gantry, but can be performed outside MRI with transrectal ultrasound (TRUS) –MRI fusion. Relative costs were compared between the two approaches.
To evaluate the potential of sequential MR image –guided local immune checkpoint blockade immunotherapy using multifunctional carriers after a prechemotherapy in prostate cancer (PC).
Publication date: Available online 18 February 2020Source: Seminars in Ultrasound, CT and MRIAuthor(s): Devaki Shilpa Sudha Surasi, Brian Chapin, Chad Tang, Gregory Ravizzini, Tharakeswara Kumar BathalaAbstractProstate cancer (PCa) is the most common non-cutaneous malignancy in men and the second leading cause of cancer related death in the United States. Men with clinical suspicion of PCa undergo tissue sampling and based on features including the Gleason score, Prostate Specific antigen (PSA) levels and clinical tumor (T) stage, patients are risk stratified into 6 major groups based on National Comprehensive Cancer Netwo...
Abstract PURPOSE: Prostate cancer (PCa) is one of the most common cancers in elderly men worldwide. Systematic biopsy guided by transrectal ultrasound remains the standard for PCa diagnosis; however, the false negative rate is 10-20%. Multiparametric magnetic resonance imaging (mpMRI) allows PCa visualization with a more precise localization and a higher accuracy and specificity for the detection of PCa. The physician can mentally relocate the most appropriate area detected on the prebiopsy mpMRI, based on its zonal topography and anatomical landmarks, called cognitive fusion. Herein, we concentrated on the accura...
Abstract OBJECTIVE: To analyze prostatic-specific antigen density (PSAD) according to the Prostate Imaging Reporting and Data System (PIRADSv.2) score, in order to determine how it should be used. METHODS: This correlative series considered 952 men with prostatic-specific antigen>3 ng/ml and/or abnormal digital rectal examination who were subjected to prostatic biopsy (PB) between 2016 and 2017. Of these men, 768 had no previous 5-α-reductase inhibitor use or history of prostate cancer (CaP) and had previously undergone 3-T multiparametric magnetic resonance imaging (mpMRI). In this sample, 549 men w...